Vanguard Group
FTH

Vanguard Group’s Faeth Therapeutics FTH Stock Holding History

Vanguard Group’s Portfolio FTH Stock Details FTH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-29,090
Closed -$250K – 4416
2025
Q2 		$250K Sell
29,090
-189
-0.6% -$1.36K ﹤0.01% 4051
2025
Q1 		$231K Sell
29,279
-444
-1% -$4.22K ﹤0.01% 4040
2024
Q4 		$291K Sell
29,723
-1,215
-4% -$12.2K ﹤0.01% 4048
2024
Q3 		$370K Hold
30,938
– – ﹤0.01% 4042
2024
Q2 		$384K Buy
30,938
+2,246
+8% +$46.7K ﹤0.01% 4066
2024
Q1 		$603K Buy
28,692
+9
+0% +$155 ﹤0.01% 3969
2023
Q4 		$397K Hold
28,683
– – ﹤0.01% 4098
2023
Q3 		$459K Hold
28,683
– – ﹤0.01% 4075
2023
Q2 		$654K Hold
28,683
– – ﹤0.01% 4033
2023
Q1 		$860K Hold
28,683
– – ﹤0.01% 3967
2022
Q4 		$855K Buy
28,683
+10
+0% +$294 ﹤0.01% 3958
2022
Q3 		$889K Sell
28,673
-4,806
-14% -$189K ﹤0.01% 4043
2022
Q2 		$1.52M Sell
33,479
-4,319
-11% -$162K ﹤0.01% 3932
2022
Q1 		$1.75M Buy
37,798
+113
+0.3% +$8.99K ﹤0.01% 4012
2021
Q4 		$4.37M Buy
37,685
+347
+0.9% +$51.8K ﹤0.01% 3687
2021
Q3 		$7.86M Buy
37,338
+17,950
+93% +$3.27M ﹤0.01% 3384
2021
Q2 		$3.78M Buy
19,388
+3,153
+19% +$779K ﹤0.01% 3735
2021
Q1 		$4.72M Buy
+16,235
New +$5.43M ﹤0.01% 3561

Other funds holding FTH

IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
CCM
Catalio Capital Management New York $479M AUM 140.7% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
SS
SBI Securities Tokyo, Japan $4.4B AUM 74.26% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return

Vanguard Group's FTH Position: Q3 2025 in Review

Vanguard Group sold out of Faeth Therapeutics (FTH) in Q3 2025, closing a stake of 29,090 shares — an estimated $250K sold.

Vanguard Group first reported a position in FTH in Q1 2021 and held it in 18 quarters. The position peaked at $7.86M in Q3 2021. 9 funds tracked by Wall St. Rank hold FTH as of Q3 2025.

  • Vanguard Group reported no remaining Faeth Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Vanguard Group sold 29,090 Faeth Therapeutics shares in Q3 2025, an estimated $250K.
  • Vanguard Group first reported a position in Faeth Therapeutics in Q1 2021 and held it in 18 quarters.
  • Vanguard Group's Faeth Therapeutics position peaked at $7.86M in Q3 2021.
  • 9 funds tracked by Wall St. Rank held Faeth Therapeutics as of Q3 2025.

Based on Vanguard Group's 13F filing for Q3 2025, filed 7 Nov 2025.